NCT04462952已完成1 期
A Phase I, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-Tumour Activity of Adavosertib (AZD1775) in Monotherapy and in Combination With Chemotherapy in Japanese Patients With Advanced Solid Tumours
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- AstraZeneca
- 入组人数
- 6
- 试验地点
- 1
- 主要终点
- Incidence of Dose-limiting toxicity (DLTs)
研究概览
简要总结
This is a phase I, open-label study to assess the safety, tolerability, pharmacokinetics(PK) and anti-tumour activity of adavosertib in Japanese patients with advanced solid tumours. This study consists of 2 parts, monotherapy (part A) and chemotherapy combination (part B). At least 3, or up to 6, evaluable Japanese patients with advanced solid tumours will be enrolled in each cohort to confirm the tolerability.
详细描述
Objectives:
Primary objective:
Part A:
To assess the safety and tolerability, describe any dose-limiting toxicity (DLT) for adavosertib
Secondary objective:
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 120 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Japanese patients ≥20 years of age at the time of study entry
- •Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0, 1
- •Adequate bone marrow reserve or organ function
- •Female patients who are not of child-bearing potential, and fertile females of childbearing potential who agree to use adequate contraceptive measures
- •Male patients should be willing to use barrier contraception
- •Predicted life expectancy ≥12 weeks
- •Part A : Histologically or cytologically documented locally advanced or metastatic solid tumour, excluding lymphoma, for which standard therapy does not exist or has proven ineffective or intolerable
- •Part B : Histologically or cytologically documented locally advanced or metastatic solid tumour, excluding lymphoma, for which standard therapy does not exist or has proven ineffective or intolerable and additionally, tumours for which gemcitabine is expected to be effective.
- •Measurable or non-measurable disease according to RECIST v1.1
排除标准
- •Use of anti-cancer treatment drug ≤21 days or 5 half-lives (whichever is shorter) prior to Cycle 1 Day 1
- •Use of an investigational drug during the past 30 days or 5 half-lives (whichever is longer) prior to Cycle 1 Day 1
- •Common Terminology Criteria for Adverse Events (CTCAE) Grade >1 toxicity from prior therapy
- •Inability to swallow oral medication or any other condition that may impact adavosertib intake/absorption
- •Known malignant central nervous system (CNS) disease other than neurologically stable, treated brain metastases
- •Any of the cardiac diseases currently or within the last 6 months
- •Any underlying medical condition that would impair the patient's ability to receive study treatment
- •Other invasive malignancy within 5 years prior to Cycle 1 Day 1 except for non-invasive malignancies
- •Part B : Presence of apparent radiological findings for interstitial pneumonitis or pulmonary fibrosis with pulmonary symptoms
研究组 & 干预措施
Adavosertib (AZD1775) monotherapy
Experimental
Dose escalation of adavosertib monotherapy for patients with advanced solid tumours
干预措施: Adavosertib (AZD1775) (Drug)
Adavosertib (AZD1775) in combination with gemcitabine
Experimental
Dose escalation of adavosertib in combination with gemcitabine for patients with advanced solid tumours
干预措施: Adavosertib (AZD1775) (Drug)
结局指标
主要结局
Incidence of Dose-limiting toxicity (DLTs)
时间窗: From the first dose of Cycle 1 up to the assessment prior to the planned first dose of Cycle 2 (each cycle is 21 days for Part A and 28 days for Part B)
Investigate the safety and tolerability of adavosertib
Incidence of Adverse events
时间窗: From the informed consent to 30 days post last dose
Investigate the safety and tolerability of adavosertib
次要结局
- Time of maximum plasma drug concentration observed (tmax).(Part A:Samples will be collected on Cycle1Day1,5, C2D5, C3D5 and C5D5. Part B:Samples will be collected on C1D2,3 and even Cycle D2 for adavosertib and C1D1 for gemcitabine. (each cycle is 21 days for Part A, 28 days for Part B))
- trough plasma concentration (Ctrough).(Part A:Samples will be collected on Cycle1Day1,5, C2D5, C3D5 and C5D5. Part B:Samples will be collected on C1D2,3 and even Cycle D2 for adavosertib and C1D1 for gemcitabine. (each cycle is 21 days for Part A, 28 days for Part B))
- Maximum plasma drug concentration observed (Cmax).(Part A:Samples will be collected on Cycle1Day1,5, C2D5, C3D5 and C5D5. Part B:Samples will be collected on C1D2,3 and even Cycle D2 for adavosertib and C1D1 for gemcitabine. (each cycle is 21 days for Part A, 28 days for Part B))
- Disease control rate (DCR)(Assessed every 9 weeks in Part A and every 8 weeks in Part B with RECIST from the first dose of adavosertib until disease progression. Expected to be for up to 3 months.)
- Area under the plasma concentration-time curve from zero to 24 hours (AUC0-24).(Part A:Samples will be collected on Cycle1Day1,5, C2D5, C3D5 and C5D5. Part B:Samples will be collected on C1D2,3 and even Cycle D2 for adavosertib and C1D1 for gemcitabine. (each cycle is 21 days for Part A, 28 days for Part B))
- Objective response rate (ORR)(Assessed every 9 weeks in Part A and every 8 weeks in Part B with RECIST from the first dose of adavosertib until disease progression. Expected to be for up to 3 months.)
- Progressionfree free survival (PFS)(Assessed every 9 weeks with RECIST from the first dose of adavosertib until disease progression. Expected to be for up to 3 months.)
- Duration of response (DoR)(Assessed every 9 weeks in Part A and every 8 weeks in Part B with RECIST from the first dose of adavosertib until disease progression. Expected to be for up to 3 months.)
- Part B: the drug interaction between adavosertib and gemcitabine.(Part B : Samples will be collected on Cycle 1 Day 2,3 and even Cycle Day 2 for adavosertib and Cycle 1 Day 1 for gemcitabine. (each cycle is 28 days))
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Study of AZD9150 and MEDI4736 (Durvalumab) in Japanese Adult Patients With Advanced Solid MalignanciesAdvanced Solid MalignanciesNCT03394144AstraZeneca11
已完成
1 期
A Phase I Study of MEDI9447 (Oleclumab) in Japanese PatientsAdvanced Solid MalignanciesNCT03736473AstraZeneca6
已完成
1 期
An Open-Label Phase 1 Study of Ceralasertib in Japanese Patients With Advanced Solid MalignanciesAdvanced Solid MalignanciesNCT05469919AstraZeneca12
已完成
1 期
A Phase 1 Study of AZD9833 in Japanese Women With ER Positive, HER2 Negative Advanced Breast CancerER+ HER2- Advanced Breast CancerNCT04541433AstraZeneca10
已完成
1 期
A Phase I Study of AZD4635 in Japanese Patients With Advanced Solid MalignanciesAdvanced Solid MalignanciesNCT03980821AstraZeneca10